uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company's product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington's disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington's disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:QURE
- CUSIP: N/A
- Web: www.uniqure.com
- Market Cap: $142.78 million
- Outstanding Shares: 25,227,000
- 50 Day Moving Avg: $5.33
- 200 Day Moving Avg: $5.94
- 52 Week Range: $4.72 - $14.59
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.33
- P/E Growth: 0.00
- Annual Revenue: $25.1 million
- Price / Sales: 5.69
- Book Value: $2.52 per share
- Price / Book: 2.25
- EBIDTA: ($65,940,000.00)
- Net Margins: -370.57%
- Return on Equity: -70.75%
- Return on Assets: -30.99%
- Debt-to-Equity Ratio: 0.25%
- Current Ratio: 7.34%
- Quick Ratio: 7.33%
- Average Volume: 111,719 shs.
- Beta: 0.15
- Short Ratio: 6.14
Frequently Asked Questions for Uniqure NV (NASDAQ:QURE)
What is Uniqure NV's stock symbol?
Uniqure NV trades on the NASDAQ under the ticker symbol "QURE."
How were Uniqure NV's earnings last quarter?
Uniqure NV (NASDAQ:QURE) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.16. The business had revenue of $3.32 million for the quarter, compared to the consensus estimate of $4.20 million. Uniqure NV had a negative return on equity of 70.75% and a negative net margin of 370.57%. View Uniqure NV's Earnings History.
When will Uniqure NV make its next earnings announcement?
Where is Uniqure NV's stock going? Where will Uniqure NV's stock price be in 2017?
8 brokerages have issued 12-month price targets for Uniqure NV's shares. Their forecasts range from $8.00 to $27.00. On average, they expect Uniqure NV's share price to reach $16.57 in the next year. View Analyst Ratings for Uniqure NV.
What are analysts saying about Uniqure NV stock?
Here are some recent quotes from research analysts about Uniqure NV stock:
- 1. Cowen and Company analysts commented, "QURE reported 1Q17 financials and presented multiple updates at ASGCT recently." (5/24/2017)
- 2. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (5/17/2017)
Are investors shorting Uniqure NV?
Uniqure NV saw a drop in short interest in April. As of April 28th, there was short interest totalling 791,926 shares, a drop of 1.7% from the April 13th total of 805,786 shares. Based on an average trading volume of 103,086 shares, the short-interest ratio is currently 7.7 days.
Who are some of Uniqure NV's key competitors?
Some companies that are related to Uniqure NV include Sinovac Biotech (SVA), Compugen (CGEN), Veracyte (VCYT), Nabriva Therapeutics AG - (NBRV), Dynavax Technologies (DVAX), Minerva Neurosciences (NERV), SIGA Technologies (SIGA), Akebia Therapeutics (AKBA), Kamada Ltd (KMDA), Ardelyx (ARDX), Idera Pharmaceuticals (IDRA), Curis (CRIS), Anavex Life Sciences Corp. (AVXL), Abeona Therapeutics (ABEO), Cerus (CERS), Aratana Therapeutics (PETX), Chimerix (CMRX) and Codexis (CDXS).
Who owns Uniqure NV stock?
Uniqure NV's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (5.94%), Perceptive Advisors LLC (5.02%), Morgan Stanley (2.24%), Renaissance Technologies LLC (1.48%), Spark Investment Management LLC (1.22%) and Boston Partners (1.07%). View Institutional Ownership Trends for Uniqure NV.
Who sold Uniqure NV stock? Who is selling Uniqure NV stock?
Who bought Uniqure NV stock? Who is buying Uniqure NV stock?
Uniqure NV's stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, P.A.W. Capital Corp, Renaissance Technologies LLC, Paloma Partners Management Co, Morgan Stanley, Weiss Multi Strategy Advisers LLC, Oxford Asset Management and JPMorgan Chase & Co.. View Insider Buying and Selling for Uniqure NV.
How do I buy Uniqure NV stock?
Shares of Uniqure NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Uniqure NV stock cost?
One share of Uniqure NV stock can currently be purchased for approximately $5.66.
Earnings History for Uniqure NV (NASDAQ:QURE)Earnings History by Quarter for Uniqure NV (NASDAQ:QURE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/29/2017|| || || || || || || || |
|5/9/2017||3/31/2017||($0.64)||($0.80)||$4.20 million||$3.32 million||View||N/A|
|5/31/2016||Q1||($0.82)||($0.93)||$2.94 million||$4.30 million||View||N/A|
|4/4/2016||Q415||($0.60)||($0.58)||$2.78 million||$6.78 million||View||N/A|
|11/30/2015||Q315||($0.64)||($1.14)||$7.76 million||$3.50 million||View||Listen|
|8/27/2015||Q215||($0.56)||($0.98)||$31.18 million||$1.79 million||View||N/A|
|6/11/2015||Q1||($0.82)||($0.69)||$9.50 million||$1.17 million||View||N/A|
|4/6/2015||($0.62)||($0.77)||$1.38 million||$1.61 million||View||N/A|
|12/1/2014||($0.53)||($0.61)||$2.00 million||$1.30 million||View||N/A|
|9/2/2014||Q214||($0.55)||($1.35)||$1.40 million||$1.37 million||View||N/A|
|6/6/2014||($0.45)||($0.52)||$0.84 million||$1.59 million||View||N/A|
Earnings Estimates for Uniqure NV (NASDAQ:QURE)
2017 EPS Consensus Estimate: ($2.73)
2018 EPS Consensus Estimate: ($2.44)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Uniqure NV (NASDAQ:QURE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Uniqure NV (NASDAQ:QURE)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Uniqure NV (NASDAQ:QURE)
Latest Headlines for Uniqure NV (NASDAQ:QURE)
Uniqure NV (QURE) Chart for Thursday, May, 25, 2017